Molecular Signatures of Lymphoma

Progress in Hematology

DOI: 10.1532/IJH97.04133

Cite this article as:
Savage, K.J. & Gascoyne, R.D. Int J Hematol (2004) 80: 401. doi:10.1532/IJH97.04133


Hematologic malignancies have historically been characterized by morphologic, immunophenotypic, molecular, and genetic features. However, morphologically identical tumors can have clearly distinct clinical outcomes, suggesting underlying biological heterogeneity. Recent advances in microarray technology have helped the classification of lymphoid malignancies evolve to a new refined level. In addition to the discovery of new disease subclasses defined by unique molecular profiles, gene expression patterns can be correlated with specific genetic abnormalities and prognoses. Furthermore, the discovery of new disease subtypes has provided further insight into lymphoma biology and pathogenesis. Unique gene signatures can highlight key deregulated pathways that are active in molecular disease categories, and in some cases these findings have elucidated new targets for novel therapeutic approaches. This review summarizes the current status of molecular profiling in non-Hodgkin lymphomas. In this review, we have endeavored to include data from multiple investigator groups and tried to cover the breadth of lymphoid tumors, excluding acute and chronic leukemias.

Key words

LymphomaMicroarray profilingGene expression

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  1. 1.Divisions of Medical OncologyUniversity of British ColumbiaVancouverCanada
  2. 2.Divisions of Pathology, British Columbia Cancer AgencyUniversity of British ColumbiaVancouverCanada